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Inclusion of cost effectiveness in licensing requirements of
new drugs: the fourth hurdle
R S Taylor, M F Drummond, G Salkeld, S D Sullivan
Increasing numbers of countries are considering cost effectiveness in decisions about which drugs to
make available for prescription. How do the different approaches work and is it time for
standardisation?
Licensing is the main method of regulating and
controlling access to pharmaceuticals. New drugs
cannot receive a product licence until manufacturers
provide evidence of their quality, safety, and efficacy. In
a world of rapidly escalating global healthcare costs,
evidence of a drug’s quality, safety, and efficacy is no
longer sufficient to ensure reimbursement for use in
public markets. Increasingly, new drugs must show evi-
dence of cost effectiveness. In other words, does the
drug produce a useful health gain (over and above cur-
rently available treatments) for its additional cost? In
industry circles this value for money requirement has
become known as the fourth hurdle. In this article, we
examine the international development of fourth
hurdle policies, analyse their effect, and identify some
of the future challenges and likely directions.
Emergence of the fourth hurdle
The first healthcare system to develop formal
regulations governing the use of cost effectiveness evi-
dence in reimbursement decisions was Australia. Since
1993, the Australian Pharmaceutical Benefit Scheme
has insisted on appropriate economic evidence before
authorising public funding of a new drug.1 Once the
Pharmaceutical Benefits Advisory Committee receives
a submission from a pharmaceutical company, it is
appraised in an explicit process that deconstructs the
evidence provided by the manufacturer. The commit-
tee considers the evidence on cost effectiveness as one
of several potentially important factors when advising
the health minister on whether to list the drug for
reimbursement. These include:
x The importance of the clinical area
x The availability of alternative treatments
x The likely effect of listing on the healthcare system
and other therapeutic activities
x The investment of the sponsor in primary research.
The committee may therefore accept a higher price
for a “breakthrough” product that has required the
sponsor to invest substantially in primary research
than for subsequent drugs with similar action (“me
too” drugs) when these have an equivalent group
effect. However, relative cost effectiveness is considered
the most important criterion.
In September 1994, the Canadian Province of
Ontario followed the Australian lead in issuing guide-
lines for the economic evaluation of a drug. Since Sep-
tember 1995, submissions for listing of new drugs on
the Ontario provincial formulary have been deemed to
be incomplete if they do not contain an economic
analysis or justify its absence.2
Global development
Faced with greatly increasing drug budgets (see box 1)
many countries, particularly in Europe, have begun to
use economic evidence in national reimbursement
decisions.
Europe
Probably the most important fourth hurdle develop-
ment in Europe has been the technology appraisal
programme of the UK’s National Institute for Clinical
Excellence (NICE). In its first few years, NICE has
attracted much attention and criticism and is seen by
some as a potential model of a pan-European fourth
hurdle agency.3–5
A few countries have introduced a formal require-
ment for the consideration of economic evidence as
part of the pricing or reimbursement decision. These
include Belgium, Finland, Norway, Portugal, and
Sweden. The Netherlands has indicated the intention
to introduce a formal requirement but has postponed
this until 2005. Just recently, Hungary has become one
of the first Eastern European countries to signal the
introduction of a formal requirement for economic
evidence. Germany has recently established an
institute, which may have an evaluation function, and
there is some health technology assessment at a
regional level in Spain. In several other countries,
including Denmark, France, and Italy, the submission
of economic evidence (by companies) is voluntary, but
may be considered when it is submitted.
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United States
Like Europe, the United States has only recently
started to use economic evaluation in drug listing deci-
sions. In 1998, Regence BlueShield, a health manage-
ment organisation, began requesting clinical and
economic evidence from pharmaceutical and biophar-
maceutical manufacturers as a condition for formulary
review.6 In 2000, the Academy of Managed Care Phar-
macy (AMCP), a national professional society of man-
aged care purchasers, developed its own version of the
guidelines—the AMCP format for formulary submis-
sion.7 Although an exact figure is not known, over 50
private and public sector healthcare purchaser organi-
sations, covering well over 120 million lives, have
adopted the AMCP format or a similar process.
Rest of the world
Little has been written about use of economic
evaluation outside Australia, Europe, and North
America. For example, Japan, despite being the second
largest health care economy in the world, seems to
have done little economic evaluation and currently has
no system of limiting market entry of drugs based on
their cost effectiveness.8
Many countries are now implementing formal or
informal fourth hurdle systems that reflect the local
health economy.9 10 Box 2 outlines the requirements of
these systems (see bmj.com for illustration of the
differing approaches to these requirements in the Aus-
tralian and UK systems).
Effect of fourth hurdle
The ultimate goal of economic evaluation may be to
maximise health for a given healthcare budget, but this
is difficult to assess in practice. Here, we examine the
effect of the fourth hurdle according to three
outcomes: quality of evidence, effect on reimburse-
ment policies, and effect on price
Quality of pharmacoeconomic evidence
The problem of quality and related biases in pharmaco-
economic studies has long been recognised. Friedberg
and colleagues found that studies funded by the
pharmaceutical industry were one eighth as likely to
reach unfavourable qualitative conclusions, and 1.4
times more likely to reach favourable quantitative
conclusions as non-profit funded studies.11 The
industry related bias in economic evaluation publica-
tions has been confirmed in several subsequent
publications.12
Is the quality of pharmaceutical industry economic
submissions to fourth hurdle agencies any better than
published studies? Hill and colleagues examined all
326 submissions made to the Australian Pharmaceuti-
cal Benefit Scheme between 1994 and 1997.13 Of these
submissions, 216 (67%) were considered to present
“serious problems of interpretation.” The drug benefit
plan committees in British Columbia and Ontario
have confirmed this Australian experience. Anis et al
reported that of the 32 pharmacoeconomic studies
submitted to the two committees in 1996, only 21
could be used to make recommendations, the remain-
der being rejected because they contained incomplete
or pending information.14
We were unable to find more recent publications
examining the quality of pharmacoeconomics submit-
ted to fourth hurdle agencies. However, our collective
experience is that the quality of industry reimburse-
ment submissions has probably improved. Neverthe-
less, complex decision analysis models are being
increasingly used to support the acceptable (or not)
cost effectiveness of drugs; this move is supported by
the recent technical guidance released by NICE.15 The
models vary in quality and many are not very
transparent, making continued independent assess-
ment of models essential within the fourth hurdle
process.
Does cost effectiveness information influence
reimbursement decisions?
A central premise of the fourth hurdle approach is that
those drugs deemed to achieve acceptable cost
effectiveness are recommended while those that fail to
meet acceptable levels are more likely to be rejected.
What might constitute acceptable cost effectiveness is
beyond the scope of this article and has been discussed
elsewhere.16
George and colleagues examined 355 submissions
to the Australian Pharmaceutical Benefit System
between 1991 and 1996 and found 26 that used cost
per life year gained and nine that used cost per quality
adjusted life year (QALY).17 Raftery conducted a
similar exercise based on the decisions of the NICE
technology appraisal programme up to March 2001.18
From these two studies it is possible to compare the
cost per life year gained or QALY of drugs that have
Box 1: Why are drug budgets rising? (adapted
from Stevens et alw15)
The unit cost of new drugs has been higher than that of the
drug they replace— for example, selective serotonin
reuptake inhibitors cost six times as much as the older
tricyclic antidepressants,w1 taxanes are several
thousand pounds per patient more expensive than
previous anticancer drugs, w2 w3 and two drugs for
severe rheumatoid arthritis—etanercept and
infliximab—can cost nearly £10 000 per patient for
every year that they are treated.w4
Drugs are being developed for many conditions that have
previously had no treatment— for example, lifestyle drugs
(such as sildenafil for erectile dysfunctionw5 and
buproprion for stopping smokingw6) and designer
drugs often produced by the biotechnology industry
to treat uncommon diseases w7
The introduction of a drug can place a demand on the use of
other expensive technologies—for example, the effective
use of the anti-flu drug, zanamivir, is aided by a near
patient diagnostic test to confirm flu-like illness.w8
Moreover, delivery of drugs may depend on other
medical technology—for example, insulin pumps for
diabetics, w9 intrathecal morphine pumps for chronic
back pain, w10 and, more recently, the development of
drug eluting coronary artery stents coated with
anticoagulant glycoproteins.w11
Box 2: Stages in leaping the fourth hurdle
• Statement of information needs of decision maker
• Submission of evidence
• Critical assessment of evidence
• Appraisal or decision making
• Issuance of guidance policy
Education and debate
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been recommended for funding versus those drugs
that have been rejected. The threshold above which
drugs were regarded as not providing good value for
money seems to be $A76 000 (£30 000, $53 500,
€44 000) per life year gained and $A42 000 per QALY
in the Australian study and £30 000 per life year
gained or QALY in the NICE study.
Although broadly supportive of the objective of
efficiency, both case series show that decision makers
do not operate against a fixed willingness to pay
threshold as an absolute decision rule. Other factors
that can influence policy decisions include the overall
budget impact of the drug (that is, the overall cost of
introducing a drug to the health system); the rule of
rescue (that is, funding a drug for a serious clinical
condition on the grounds that alternative therapies are
lacking or inadequate); and decisions around so called
lifestyle drugs (such as sildenafil).
Effect of cost effectiveness analysis on
price
An important potential consequence of including an
assessment of cost effectiveness in licensing decisions is
more efficient relative pricing. Indeed, reduced drug
costs may be a specific objective in particular
jurisdictions.
Drugs listed on the Australian Pharmaceutical
Benefit Scheme have consistently been priced below
the world average. The Bureau of Industry Economics
estimated that in 1991 the prices of drugs in Australia
were 30% below the European Union average and
about 50% below the world average.19 A key question is
whether the drug price differentials observed in 1991
have widened or narrowed as a result of the fourth
hurdle requirement.
Australian drug prices have been compared with
those in countries with similar and dissimilar subsidy
arrangements.w14 Prices have been compared for new
innovative drugs, “me too” drugs, and generic drugs.
Overall, the greatest price differentials between
Australia and other countries are for “me too” and
generic drugs (see bmj.com). Price differentials are
smaller for innovative drugs with the exception of the
United States (where prices are 104% higher). This is
at least consistent with the objective of cost
effectiveness in fourth hurdle systems, whereby price
is set in relation to the value of the additional benefit
of the drug with clinically superior drugs being
rewarded with a higher price. This review of
international drug prices concludes that “in very
broad terms, it is difficult to find any obvious associa-
tions between the observed price differences and the
types of subsidy and cost containment policies
adopted in the comparison countries.” It may be that
the biggest effect of fourth hurdle schemes on drug
costs is not through individual drug prices but in bet-
ter defining the appropriate clinical indications for the
use of medicines.20
Harmonising fourth hurdle systems
An inevitable consequence of the global growth of the
fourth hurdle has been the development of a wide
range of differing systems—both in terms of processes
and methods. This is exemplified by the proliferation
of guidelines for economic submissions; a recent
review identified over 25 different guidelines across
Europe and North America.9
Several new drugs have been deemed to have
acceptable cost effectiveness in one jurisdiction but
been rejected in another (for example, zanamivir for
the treatment of flu, riluzole for motor neuron disease,
and interferon beta for multiple sclerosis). Variations in
methods and processes across these countries may be
contributing to these differences. A lesser but
nevertheless potentially important effect of the
differing fourth hurdle requirements across countries
has been the inefficiency resulting from pharmaceuti-
cal manufacturers having to invest in often substan-
tially differing submissions for a new drug in order to
meet local requirements.
Although differences in decision making proce-
dures and societal willingness to pay pharmaceutical
policies between countries are likely to continue, the
time seems right for a greater degree of harmonisation
of methods. Drummond has recently outlined the
issues to be considered in such a convergence of
economic evaluation guidelines.21
Confidentiality and openness
A lack of confidentiality and openness presents
challenges for the fourth hurdle.22 The Australian
system is probably one of the starkest examples of a
closed system that affords the industry a high level of
confidentiality. Not only are the reasons behind its list-
ing decisions not made publicly available, but, of even
more concern, its negative decisions are not published
at all. Should pharmaceutical companies be allowed to
continue to submit data in confidence to public
funding systems, including licensing?
Greater transparency in the decision making
process will require industry to relax some of the
constraints on the commercial in confidence nature of
information they provide. Finally, openness encour-
ages the considerable potential for collaboration
between countries when evaluating pharmaceuticals.
Contributors and sources: All authors contributed to the design
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Summary points
Licensing of drugs has traditionally been based
on quality, safety, and efficacy
Faced with increasing healthcare costs, many
countries are now also requiring evidence of cost
effectiveness—the fourth hurdle
The limited evidence available suggests fourth
hurdle policies have contributed to more cost
effective use of drugs
Increasing international harmonisation and
greater openness could improve the operation of
fourth hurdle systems
Education and debate
974 BMJ VOLUME 329 23 OCTOBER 2004 bmj.com
review panels and a member of the York Technology
Assessment Group. GS is an associate professor of health eco-
nomics and a past member of the economics subcommittee,
Pharmaceutical Benefits Advisory Committee, Australia. SDS is
a member of the Premera Blue Cross Pharmacy and
Therapeutics Committee and Director of the University of
Washington Pharmaceutical Outcomes Research and Policy
Program that undertake technology assessments for govern-
ment and private concerns.
Competing interests: None declared.
1 Commonwealth Department of Health, Housing and Community Serv-
ices. Guidelines for the pharmaceutical industry on preparation of submissions
to the Pharmaceutical Benefits Advisory Committee. Canberra: Australian
Government Printing Service, 1992. www.health.gov.au/pbs/pharm/
pubs/guidelines/content.htm (accessed 5 May 2004).
2 Ontario Drug Benefits Program. Ontario guidelines for drug submission and
evaluation. www.health.gov.on.ca/english/providers/pub/drugs/
dsguide/dsguide_mn.html (accessed 1 May 2004).
3 Hutton J, Maynard A. A NICE challenge for health economics. Health
Economics 2000;9:89-93.
4 Benjamin I, Poston G, Sherlock D. Is the NICE process flawed? Lancet
2002;359:2120.
5 McKee M, Maclehose L, Mossialos E. After NICE: where now for health
policy in the European Union? J R Soc Med 2003;96:1-2.
6 Mather DB, Sullivan SD, Augenstein D, Fullerton DS, Atherly D. Incorpo-
rating clinical outcomes and economic consequences into drug
formulary decisions: a practical approach. Am J Manag Care 1999;5:277-
85.
7 Sullivan SD, Lyles A, Luce B, Gricar J. AMCP guidance for submission of
clinical and economic evaluation data to support formulary listing in US
health plans and pharmacy benefits management organizations. J Manag
Care Pharm 2001;7:272-82.
8 Oliver A. Health economic evaluation in Japan: a case study of one aspect
of health technology assessment. Health Policy 2003;63:197-204.
9 Hjelmgren J, Berggren F, Andersson F. Health economic guidelines—
similarities, differences and some implications. Value in Health 2001;4:
225-50.
10 Guillen AM, Cabiedes L. Reforming pharmaceutical policies in the Euro-
pean Union: A “penguin effect”? Int J Health Serv 2003;33:1-28.
11 Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL. Evaluation of
the conflict of interest in economic analyses of new drugs used in oncol-
ogy. JAMA 1999;282:1453-7.
12 Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry
sponsorship and research outcome and quality: systematic review. BMJ
2003;326:1167-70.
13 Hill SR, Mitchell AS, Henry DA. Problems with the interpretation of
pharmacoeconomic analyses. A review of submissions to the Australian
Pharmaceutical Benefits Scheme. JAMA 2000;283;2116-21.
14 Anis AH, Rahman T, Schechter MT. Using pharmacoeconomic analysis
to make drug insurance coverage decisions. Pharmacoeconomics
1998;13:119-26.
15 National Institute for Clinical Excellence. Guide to methods of technology
appraisal. London: NICE, 2004. www.nice.org.uk/page.aspx?o = 201974
(accessed 5 May 2004).
16 Olsen JA, Smith RD. Theory versus practice: a review of “willingness to
pay” in health and health care. Health Economics 2001;10:201-8.
17 George B, Harris A, Mitchell A. Cost-effectiveness and the consistency of
decision-making. Evidence from pharmaceutical reimbursement in Aus-
tralia (1991 to 1996). Pharmacoeconomics 2001;19:1103-9.
18 Raftery J. NICE faster access to modern treatments? Analysis of guidance
on health technologies. BMJ 2001;323:1300-3.
19 Bureau of Industry Economics. The pharmaceutical industry: impediments
and opportunities. (Evaluation report 11). Canberra: BIE, 1991.
20 Salkeld G, Mitchell A, Hill S. Pharmaceuticals. In: Mooney G, Scotton R,
eds. Economics and Australian health policy. Sydney: Allen and Unwin,
1999:115-36.
21 Drummond MF. Will there ever be a European drug pricing and
reimbursement agency? Eur J Health Econ 2003; 4:67-9.
22 Drummond M. Should commercial-in-confidence data be used by
decision makers when making assessments of cost effectiveness? App
Health Econ Health Policy 2002;1:53-4.
(Accepted 24 August 2004)
Q&A
Treating chronic inflammation of the Achilles tendon
Question
I have chronic Achilles tendinitis. An MRI scan has
shown a few small foci of cystic degeneration within
the thickened tendon. I am 63 and desperate to find a
specialist in this field as I have had acute intermittent
pain day and night for more than a year.
Elizabeth M Theo, supply teacher, Surrey
Answer
I recommend you to go to a physiotherapist and
undergo phonophoresis with flufenamic acid gel. You
may have to continue the therapy for at least two to
three weeks, and you may feel an increase in your
problem during the treatment days, but you will get
better as the therapy ends. Please don’t ever resort to a
local corticosteroid injection.
Milind M Deshpande, consultant orthosurgeon, Hubli,
India
Answer
May I add to the excellent advice of the previous
correspondent. Once you have reached maximum
medical improvement I would suggest you start a
programme of gradually increasing barefoot walking.
Choose irregular terrain, grass, sand, etc. Don’t worry
too much about impact on harder ground, even
bitumen. I would do this on alternate days at first, later
daily, but take the weekend or other two consecutive
days off. Your feet will greatly appreciate being
reminded of their original purpose and function and
reward you richly. Needless to say, high heels would be
as much a no-no as steroid injections.
Herbert H Nehrlich, private practice, Bribie Island,
Australia
Answer
Have you heard of the Bowen technique? I have
successfully treated a patient with a very thickened,
scarred, and inflamed Achilles tendon. After pelvic,
knee, and ankle procedures done over a short series of
visits, this patient’s Achilles tendon was far less
inflamed and the patient was happily able to play
tennis again.
The Bowen technique is a soft tissue therapy
involving small and gentle moves across muscle and
tendon fibres. Part of the aftercare involves walking,
which backs up the second response to your question.
Isobel Knight, Bowen therapist, Cambridge
Answer
1 Use a soft shoe without a heel cap so as to reduce the
mechanical inflammatory tendinitis
2 Use an ice pack daily for 15 minutes, moving it in
circles
3 Apply diclofenac gel locally with gentle massage and
stretch
4 Walk with a cane in the opposite hand.




This exchange was posted on the Q&A section of bmj.com. If
you want to respond to the question, or ask a new question of
your own, follow the link above or go to
http://bmj.com/q&a
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